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Risperidone in Preschool Children 
with Autistic Spectrum Disorders: 
An Investigation of Safety and Efficacy
Joan Luby, M.D.,1 Christine Mrakotsky, Ph.D.,2 Melissa Meade Stalets, M.A.,1
Andy Belden, Ph.D.,1 Amy Heffelfinger, Ph.D.,3 Meghan Williams, B.A.,1
and Edward Spitznagel, Ph.D.4
ABSTRACT
Introduction: Early intervention in autism spectrum disorders (ASDs) appears promising and
may represent a window of opportunity for more effective treatment. Whereas the safety and
efficacy of risperidone have been established for children aged 5 and older, they has not been
adequately tested in preschool children. 
Methods: A randomized placebo-controlled study of risperidone in preschool children was
conducted in a sample of young children, most of whom were also undergoing intensive be-
havioral treatment.
Results: Preschool children tolerated low-dose risperidone well with no serious adverse ef-
fects observed over a 6-month treatment period. Weight gain and hypersalivation were the
most common side effects reported, and hyperprolactinemia without lactation or related
signs was observed. Significant differences between groups found at baseline complicated
the analyses; however, controlling for some of these differences revealed that preschoolers on
risperidone demonstrated greater improvements in autism severity. The change in autism se-
verity scores from baseline to 6-month follow up for the risperidone group was 8% compared
to 3% for the placebo group. Notably, both groups significantly improved over the 6-month
treatment period.
Conclusions: Study findings suggest that risperidone is well tolerated in preschoolers over
a 6-month period, but that only minimally greater improvement in target symptoms was evi-
dent in the risperidone group, possibly due to the differences between groups at baseline or
due to the small sample size. Although these findings are not sufficient to direct treatment,
they suggest that larger-scale, double-blind, placebo-controlled investigations of risperidone
in preschoolers with ASDs should now be conducted.
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INTRODUCTION
AUTISM SPECTRUM DISORDERS (ASDs) are agroup of chronic disorders characterized
by early childhood onset of profound impair-
ment in social relatedness, delayed and de-
viant communication, and a markedly
restricted repertoire of behavior and interests.
These core symptoms are often accompanied
by behavior disturbances, including hyperac-
tivity, poor adaptability, anxiety, aggression,
irritability, sterotypies, and self-injurious be-
havior. These nonspecific behavioral problems
are disruptive, impeding remediation of core
symptoms as well as daily living skills. A re-
cent epidemiological study reported a preva-
lence rate for ASD of 4 cases per 1,000 children
(Bertrand et al. 2001). Substantially higher
rates, 6.7 cases per 1,000, are reported when
milder forms of ASDs are accounted for. Be-
cause autism can be diagnosed in early child-
hood and autistic individuals are expected to
have a normal life span, Gerlai and Gerlai
(2004) recently noted that the number of ‘pa-
tient years’ associated with autism is second
only to Alzheimer’s disease. 
The mainstay treatment for autism for more
than a decade has been intensive behavioral
intervention. A number of treatment programs
based on this fundamental approach are avail-
able and have demonstrated effectiveness (for
review, see Schreibman, 2000). Importantly,
several studies now suggest that intensive in-
tervention before the age of 5 years provides a
window of opportunity for more effective
treatment using this modality (for review, see
Dawson et al., 2000). Early intervention during
the preschool period (or earlier) appears to be
the most promising, resulting in substantially
better outcomes than later intervention (Faja
and Dawson, 2006). This finding, taken to-
gether with basic neurodevelopmental re-
search demonstrating greater neuroplasticity
during the first 5 years of life, suggest that a
similar window of opportunity might exist for
pharmacologic interventions as well.
Pharmacological treatment of autism has
been guided by the demonstrated effective-
ness of medications in the treatment of psychi-
atric symptoms exhibited by individuals with
ASDs. Along these lines, treatment to date has
targeted the reduction of specific associated
behavioral problems such as aggression and
hyperactivity as opposed to improving the
core deficits of autism. Typical antipsychotics
were among the first medications to be studied
systematically in autistic children and have
been widely used for the control of agitation,
aggression, and self-harming behaviors (Mc-
Dougle et al. 2003). A suboptimal risk–benefit
ratio related to untoward side effects, such as
sedation, weight gain, and the risk of tardive
dyskinesia, has catalyzed the search for new
and better medications in this class.
Newer atypical antipsychotics have been
used effectively in the treatment of adults and
older children with autism (McCracken et al.
2002). Compared to conventional antipsy-
chotics, these medications have a reduced risk
of extrapyramidal and sedating side effects.
The latter is particularly important when treat-
ing children for whom social learning is still
actively developing, albeit atypically. Among
atypical antipsychotics used for the treatment
of ASDs, risperidone has been the most well-
studied agent. Studies have demonstrated that
children with ASDs treated with risperidone
display decreased aggression and self-injuri-
ous behavior (e.g., McCracken et al. 2002). As a
result, risperidone has now been identified as
the only evidence-based pharmacological
treatment for autism (McClellan and Werry
2003). Although multiple studies have demon-
strated decreases in impulsivity, aggression,
and self-harm (and even stereotypic behavior)
with use of risperidone, there is considerably
less evidence that the core social impairments
of autism can be reduced through the use of
risperidone or similar agents in children over 6
years old (McCracken et al. 2002; Shea et al.
2004; McDougle et al. 2005).
Despite lack of controlled data supporting
their safety and efficacy, preschool age chil-
dren in general (and presumably those with
ASDs) are being treated with antipsychotics at
very high rates in the community (Zito et al.
2000). Witwer and Lecavalier (2005) reported
that nearly 10% of children with ASDs under
the age of 7 were treated with antipsychotic
medications in the previous year. Pharmaco-
logic treatment at this early point in develop-
ment could pose unique promise or unique
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risk on the basis of greater neuroplasticity of
the brain during the preschool period (Vitiello
1998). For this reason, as well as known high
rates of prescribing in this age group, studies
focusing on the safety and efficacy of atypical
antipsychotics specifically in preschool age
children are needed. 
Despite the promising findings on early in-
tervention in ASDs, information on the effec-
tiveness of risperidone in the treatment of
ASDs among preschool age children is limited
to case descriptions and open-label studies.
Masi and colleagues (2001) conducted the larg-
est available open-label trial of risperidone for
preschool children aged 3.9–6.6 years with
ASDs and found improvement in the global
severity of autistic symptoms. Notably, the
core social impairments of the disorder im-
proved, with gains seen in the ability to relate
to people, increased verbal and nonverbal
communication, and reduced social with-
drawal. The authors hypothesized that the
unique and promising improvements in social
behaviors, which most previous studies in
school age samples had failed to demonstrate,
may have been related to the subjects having
received treatment earlier in life. These find-
ings, while promising, are limited by the use of
an open-label design and the inherent lack of a
control group. 
To date, only two double blind, placebo-
controlled studies investigating the efficacy of
risperidone for the treatment of ASDs are
available (McCracken et al. 2002; Shea et al.
2004). Although findings from both studies
demonstrated efficacy for the amelioration of
disruptive symptoms of the disorder in chil-
dren ranging in age from 5 to 17 years, the
study by Shea and colleagues also found im-
provements in scales measuring inappropriate
speech and lethargy/social withdrawal. An-
other limitation of the available database is
that the treatment duration of most trials is rel-
atively short, typically 8–16 weeks. Longer du-
ration of treatment is desirable for mimicking
real-life practice and providing a more rigor-
ous test for placebo effects, which may occur
early and appear robust and sustained over
the short term, particularly in this population,
but do not endure over time (Sandler and Bod-
fish 2000). In addition, longer treatment dura-
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tion is necessary to monitor for adverse effects
such as weight gain, metabolic changes, and
tardive dyskinesias. 
The goal of the present study was to exam-
ine the safety and effectiveness of risperidone
in the treatment of preschool children with
ASDs over a 6-month period. Of interest was
whether the medication was safe and well tol-
erated and whether it ameliorated the associ-
ated disruptive behavioral features and/or the
core social deficits of the disorder when this
early intervention was applied. Unique fea-
tures of this investigation were the very young
sample and the implementation of a random-
ized, double blind, placebo-controlled design
for an extended duration of treatment. The
majority of the study sample was receiving
varying amounts of Applied Behavior Analy-
sis (ABA) because it is a mandated treatment
through the local public school district for eli-
gible children. Therefore, the efficacy of
risperidone was tested in the context of a pop-
ulation in which many children were undergo-
ing an intensive behavioral intervention. To
our knowledge, this investigation is the first
double-blind, placebo-controlled trial in a
preschool-age ASD population, including
preschoolers with Pervasive Developmental
Disorder Not Otherwise Specified (PDD-
NOS). The inclusion of those with PDD-NOS
and those undergoing behavioral treatments
have been noted to be particularly important
because they mimic real world practice (Troost
et al. 2005).
MATERIALS AND METHODS
Setting and patients
This 6-month, randomized, double blind,
placebo-controlled trial was conducted in a
psychiatric outpatient clinic at Washington
University School of Medicine (WUSM) in St.
Louis between November, 1999, and Novem-
ber, 2002. The study protocol was approved by
the WUSM Institutional Review Board, and
written informed consent was obtained from a
parent or legal guardian prior to enrollment.
Parents were specifically informed about the
experimental use of the drug for ASDs, as well
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as the lack of data on safety in younger chil-
dren (e.g., effects on growth and development).
Twenty four (n = 24) preschool children be-
tween the ages of 2.5 and 6.0 years who met
Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (DSM-IV) criteria for au-
tism or PDD-NOS (American Psychiatric
Association 1994), previously diagnosed and
referred by a clinician, were recruited for par-
ticipation. Subjects were ascertained from the
child psychiatry outpatient clinic, offices of
pediatricians and neurologists, and the spe-
cial education department of local public
school districts. All subjects were random-
ized, n = 12, to each treatment group. Other
inclusion criteria at the time of enrollment in-
cluded: (1) absence of other known significant
central nervous system (CNS) disorders; and
(2) absence of significant medical problems or
other psychiatric disorders requiring pharma-
cotherapy. A complete physical exam was
performed on all study participants by a
board-certified pediatrician to rule out neuro-
logical and medical illness. In addition, partic-
ipating families were strongly encouraged to
minimize the use of adjunctive medications
and/or supplements (hormones, vitamins,
diets) over the duration of treatment.
Protocol schedule and design
Patients were consecutively assigned by an
unblinded child psychiatrist (J.L.) to risperi-
done or placebo treatment using a randomiza-
tion table obtained from the WUSM pharmacy
and derived using a standard software pack-
age. Parents and raters who conducted all
standardized assessments were blind to treat-
ment group. Due to the exploratory nature of
this study and to assure safety in this very
young study population, the treating child
psychiatrist (J.L.) was unblended and con-
ducted regular clinical assessments over the 6-
month period as follows: A baseline visit,
weekly visits during the first study month, bi-
weekly visits during the second month, fol-
lowed by monthly visits for months 3–6. A
thorough psychiatric and medical history,
mental status exam, as well as physical exam
were conducted at baseline.
Structured diagnostic assessments of autism
symptoms were conducted at baseline, 2
months, 4 months, and 6 months. Standard-
ized measures were used to assess general
cognitive and socio-emotional functioning at
baseline and after 6 months. Assessments were
completed over 2 half-day periods, including
multiple breaks and rewards to elicit maxi-
mum performance from children. Due to lim-
ited data regarding the effects of risperidone
on growth and development in young chil-
dren, height and weight and potential adverse
events were carefully monitored at each study
visit. In addition, electrocardiograms and a
battery of laboratory tests (including prolactin
and leptin) were performed at baseline, 2
months, and 6 months. Data about other med-
ical, educational and developmental interven-
tions (including hours of ABA weekly) were
obtained through parental interview or the
child’s medical record. 
Baseline assessment and efficacy measures
The central diagnostic outcome measures in-
cluded the Childhood Autism Rating Scale
(CARS) (Schopler et al. 1988), a 15-item behav-
ior rating on a 7-point Likert scale based on
clinician observation of the core social and be-
havioral symptoms of autism; and the Gilliam
Autism Rating Scale (GARS) (Gilliam 1995), a
rating scale completed by the clinician based
on parent report and direct observation of the
child’s behavior that assessed frequency of
DSM-IV autistic symptoms, including commu-
nication, social interaction, stereotypic behav-
ior, and developmental regression, all yielding
a total Autism Quotient. These were adminis-
tered at baseline, 2, 4, and 6 months by raters
blinded to treatment group status.
The following measures were administered
at baseline and 6-month endpoint. Socializa-
tion and general adaptive development were
assessed with the Vineland Adaptive Behavior
Scales, Interview Edition (VABS) (Sparrow et
al. 1984), a semistructured parent interview as-
sessing communication, social skills, daily liv-
ing skills, and motor development. The
Childhood Behavior Checklist 1.5–5 (CBCL)
(Achenbach and Edelbrock 1995) was com-
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pleted by parents to assess behavior and emo-
tion problems. Patients completed the Pre-
school Language Scale, Third Edition (PLS-3)
(The Psychological Corporation, 1992), a stan-
dardized measure to assess receptive and ex-
pressive language development. Patients
underwent an additional comprehensive de-
velopmental assessment using standardized
and experimental cognitive, neuropsychologi-
cal, and observational measures.
Medication dosing
Risperidone was administered in low doses
and titrated by the unblinded child psychia-
trist on the basis of the individual subject’s
progress and side-effect profile. The dosing
range used in the study population was nar-
row and low (0.5–1.5 mg total daily dose).
Medication was administered twice daily
when doses greater than 0.5 mg were adminis-
tered. Adjustments in dose were made as
needed, depending upon treatment response
and side effects, based on the clinical judg-
ment of the unblinded child psychiatrist.
Placebo dosing was also “titrated” to better
maintain the blind design.
Most patients in the active medication
group (90.9%) started risperidone at 0.5 mg
once daily (91.7% of placebo patients were
dispensed 0.5-mg daily doses) and mean start-
ing dose was 0.03 mg/kg/day. Mean starting
dose in the risperidone and placebo group
were similar [0.50 mg (SD 0.15) risperidone
versus 0.54 mg (SD 0.14) placebo]. With
weekly dose escalation, 81.8% of risperidone
and 66.7% of placebo patients took 1 mg (0.5
mg twice daily) after 4 weeks; 27.3% of
risperidone and 33.3% of placebo patients
were dispensed total daily doses of 1.5 mg
after 8 weeks (2 months), whereas all others
received total daily doses of 1 mg. Most pa-
tients were maintained on this schedule for
the remainder of the study. Only 1 patient in
the risperidone group was tapered from 1 mg
at 4 months to 0.5 mg at 6-month endpoint.
The final risperidone mean dose was 0.05
mg/kg/day. Mean daily final dose was 1.14
mg (SD 0.32) risperidone versus 1.38 mg (SD
0.57) placebo, which was comparable.
Safety monitoring
Treatment and side effects, including any oc-
currences of adverse events, were monitored
at each study visit by the child psychiatrist
who was not blind to the treatment condition,
to assure safety in this very young study sam-
ple. All standardized baseline and outcome as-
sessments were, however, administered by
raters blind to the treatment conditions as de-
scribed above. Physical and physiological pa-
rameters potentially affected by treatment
were assessed including height, weight, and
serum leptin and prolactin levels (known to be
elevated in older children and adults on this
medication). 
Data analyses
Preliminary analyses were conducted to ex-
amine the possibility of differences between
the two study groups (i.e., treatment and con-
trol groups) in relation to several demographic
variables. To test for these differences, t tests,
Mann–Whitney U tests, or Chi-square analy-
ses were performed. To test for the effects of
treatment over the course of four time points
as well as the potential interactions between
treatment and time, repeated measures analy-
ses of variance (ANOVA) were conducted. Be-
cause the study groups significantly differed
in autism severity at baseline, several methods
were used to adjust for these differences. Spe-
cifically, covariates were entered into factorial
or repeated measures ANOVAs to reduce the
effect of the differences in autism severity be-
tween the two groups at baseline. To account
further for the differences in autism severity at
baseline, in several analyses CARS change
scores were used as the dependent variable.
CARS change scores were created by subtract-
ing a child’s baseline CARS score from their
final CARS score obtained during the last as-
sessment. The overall treatment effects were
then estimated by comparing change scores
between the risperidone and placebo groups
with independent t-tests or Mann–Whitney U
tests (for ordinal scale data). Additional analy-
ses using covariates in these nonparametic
tests were also conducted.
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RESULTS
Sample characteristics
Twenty four children 2.5–6 years of age with
a diagnosis of an ASD participated in a 6-
month treatment trial; n = 23 of these children
were included in the analyses that follow. One
child did not meet the threshold for an ASD on
the CARS or GARS at baseline, despite having
been referred with a clinical diagnosis, and
was excluded from analyses. From the total
sample, n = 11 children were randomly as-
signed to the risperidone [mean age 49.0
months (4.1 years), SD 10.9 months] treatment
group and n = 12 preschool-age children were
assigned to the placebo group [mean age 48.1
months (4 years), SD 13.2]. The demographic
and clinical characteristics of the sample at
baseline are illustrated in Table 1. The two
groups did not differ significantly in age, gen-
der, or maternal education. The groups did
also not differ significantly with regard to the
ABA treatment. The mean number of weekly
ABA treatment hours was 21.2 for the risperi-
done group and 11.3 for the placebo group.
This difference in treatment intensity was,
however, not significant (p = 0.13).
Baseline differences between study groups
Despite using conventional methods (e.g., ran-
dom digits table) to randomize the assignment
of children to each treatment group, preschool-
ers in the risperidone group displayed signifi-
cantly greater severity of autism symptoms at
baseline as measured by the CARS (t = 2.34,
df = 21, p = 0.03). In addition, the risperidone
group had significantly poorer language skills as
measured by the PLS-3 and poorer motor skill
development as measured by the VABS Motor
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TABLE 1. BASELINE CHARACTERISTICS OF PRESCHOOL STUDY SAMPLE: RISPERIDONE VERSUS PLACEBO GROUP
Risperidone Placebo
(n = 11) (n = 12) Test of significance
Age in months: Mean (SD) 49.0 (10.9) 48.1 (13.2) p = 0.86, t = 0.18, df = 21
Gender (M/F) 9/2 8/4 p = 0.64, Fisher’s exact
Weight in kg: Mean (SD) 19.2 (3.3) 18.1 (4.2) p = 0.49, t = 0.70, df = 21
Ethnicity-Caucasian 91% 92% p = 0.37, 2 = 2.01, df = 2
Household income: Mediana 2.0 3.0 p = 0.09, U = 43.00,
>$60,000 46% 83% p = 0.12, 2 = 4.30, df = 2
Maternal Education: Medianb 6.0 6.0 p = 0.66, U = 59.00
range 4–8 4–8
ABA hours per week 21.2 (14.8) 11.3 (15.1) p = 0.13, t = 1.60, df = 21
CARS Total Score: Mean (SD)* 37.6 (4.0) 33.3 (4.9) p = 0.03, t = 2.34, df = 21
CARS Category: Median 2.0 1.0 p = 0.15, U = 44.5
Nonautistic (Cat 1) 0 (0%) 3 (25%) p = 0.19, 2 = 3.36, df = 2
Mild–moderate (Cat 2) 5 (46%) 5 (42%)
Severe (Cat 3) 6 (56%) 4 (33%)
GARS Autism Quotient SSc 91.6 (9.5) 91.3 (9.3) p = 0.94, t = 0.08, df = 21
Object Assembly Scaled Score:
>3 years Mean (SD) (n = 10/10) 5.5 (3.8) 8.1 (4.6) p = 0.19, t = 1.38, df = 18
PLS-3 Total SS* 57.3 (10.1) 73.5 (19.4) p = 0.02, t = 2.48, df = 21
VABS Communication SS 65.5 (18.5) 73.2 (8.8) p = 0.23, t = 1.26, df = 21
VABS Daily Living Skills SS 64.7 (14.8) 74.6 (15.9) p = 0.14, t = 1.54, df = 21
VABS Socialization SS 66.3 (16.3) 72.0 (16.4) p = 0.41, t = 0.84, df = 21
VABS Motor Skills SS 73.1 (18.7) 86.9 (13.4) p = 0.05, t = 2.05, df = 21
CARS = Childhood Autism Rating Scale; GARS = Gilliam Autism Rating Scale; PLS-3 = Preschool Language Scale,
Third Edition; VABS = Vineland Adaptive Behavior Scales, Interview Edition.
a1 = $0–$29,999, 2 = $30,000–$59,999, 3 = $60,000.
b1 = some grade school, 2 = completed grade school, 3 = some high school, 4 = high school diploma, 5 = some col-
lege or 2-year degree, 6 = 4-year college degree, 7 = some years beyond college, 8 = graduate or professional degree.
cSS = Standard Score (mean 100, SD 15).
*p < 0.05.
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Skills Scale (see Table 1). To account for these
baseline differences in symptom severity and de-
velopmental impairment between groups, these
key developmental variables were entered as
covariates in subsequent analyses as appropri-
ate. It should be noted that treatment groups did
not differ significantly in autism severity on the
GARS or IQ as measured by a nonverbal reason-
ing and problem-solving task (Wechsler Pre-
school and Primary Scale of Intelligence-Revised
(WPPSI-R) Object Assembly). Thus, it was not
necessary to control for the effects of these vari-
ables in the analyses that follow.
Safety of risperidone
No deaths or serious treatment-related ad-
verse events occurred during the 6-month
study period for any subject. Risperidone was
well tolerated at the low doses administered.
No clinically significant changes in EKG were
detected for any subject from baseline to fol-
low-up. The most common adverse events that
occurred were transient sedation (n = 5), in-
creased appetite (n = 6), and hypersalivation (n
= 2). Constipation was reported by the parent
of one study participant taking risperidone.
Notably, no dystonic or dyskinetic movements
were observed over the 6-month period for
any participant on risperidone.
One participant on risperidone demonstrated
transient staring spells (lasting several seconds)
and periods of apparent waxy flexibility. These
episodes were described by the parent and
teacher and reportedly occurred over a 48-hour
period after a minor head injury with visible
bruising on her head but without loss of con-
sciousness. An additional clinic visit was sched-
uled, during which time the subject was afebrile
and no abnormalities were observed on AIMS
evaluation. Although the episode was not
deemed attributable to the medication, the dose
was lowered as a precautionary measure and a
pediatric exam was recommended. The epi-
sodes spontaneously resolved within 48 hours.
It was notable that subjects on placebo also
were reported by their parents to be experienc-
ing transient sedation (n = 4) and increased ap-
petite (n = 3). One subject on placebo dropped
out of the study after 5 days due to a parental
report of severe hyperactivity after placebo
was started.
Physiologic findings
Changes in physiological measures within
study groups and analyses of group differences
in change scores are summarized in Table 2. In-
creases in prolactin serum levels were noted for
both study groups from baseline to endpoint,
with changes significantly higher [ = 0.66, F (1,
15) = 7.61, p < 0.05] in the risperidone group
from mean baseline levels of 8.11 ng/ml (SD
4.56 ng/ml) to mean endpoint levels of 41.49
ng/ml (SD 18.30 ng/ml) [vs. from 9.29 ng/ml
(SD 4.06 ng/ml) to 20.40 ng/ml (SD 18.09
ng/ml) in the placebo group]. There was a trend
(p = 0.05) for a higher increase in mean leptin
serum levels in the risperidone group from 3.09
mg/L (SD 0.79) at baseline to 5.16 mg/L (SD
4.21) at 6 months versus from 4.34 mg/L (SD
2.75) to 3.81 mg/L (SD 2.18) in the placebo
group. Most notably, children on risperidone
gained significantly more, F (1, 21) = 8.67, p <
0.01, weight than children in the placebo group,
with a mean weight gain of 2.96 kg from base-
line versus 0.61 kg in the placebo group.
Effectiveness in amelioration of autism
symptoms: Comparing the risperidone and
placebo groups at four time points
Results of primary outcome measures dur-
ing all four assessment points (baseline, 2, 4,
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TABLE 2. MEAN CHANGE SCORES OF PHYSIOLOGICAL MEASURES FROM BASELINE TO ENDPOINT
Risperidone Placebo Statistics
Measure M SD M SD t (df) p
Weight change in kg 2.96 2.53 0.61 1.10 2.94 (21) 0.008
Leptin change in mg/L 0.66 0.97 0.35 0.91 2.15 (14) 0.050
Prolactin change in ng/ml 33.38 14.48 11.11 18.74 2.76 (15) 0.015
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and 6 months) are provided in Table 3. A re-
peated measures ANOVA across all four time
points indicated that all participants’ CARS
Total Scores improved significantly over time
within the risperidone and placebo groups
combined [ = 0.37, F (3, 19) = 10.61, p < 0.001].
However, the degree of improvement was not
statistically different between the risperidone
and placebo groups. To minimize the potential
effect of group differences in autism symptom
severity at baseline, the two developmental
variables that differed between groups at base-
line (PLS-3 Total Language and VABS Motor
Skills scores) were used as covariates in
follow-up analyses. Results from the repeated
measures ANCOVA revealed no significant
differences between the risperidone and
placebo groups when the effects of preschool-
ers’ language and motor development were
controlled for statistically (see Table 3).
Effectiveness in treatment of autism
symptoms: Risperidone versus placebo at
baseline and 6-month follow up
When differences in baseline developmental
characteristics were accounted for, results in-
dicated no statistically significant differences
between the risperidone and placebo groups
on any of the outcome measures of interest
when examining all four time points. How-
ever, when the total number of intervals being
examined was reduced from four to two
points (i.e., baseline and final assessment), and
when baseline differences in motor develop-
ment between groups were accounted for, re-
peated measures analyses of autism symptom
scores on the CARS over these two time points
(baseline to 6-month study endpoint) revealed
significant differences between the study
groups [ = 0.74, F (1,21) = 6.92, p < 0.05] with a
large effect size of d = 0.95. Specifically, chil-
dren treated with risperidone demonstrated
greater improvement in autism symptom rat-
ings when compared to placebo controls (see
Table 4). Accordingly, the risperidone group
mean CARS Total scores dropped from the
“Severely Autistic” to the “Mildly to Moder-
ately Autistic” range at endpoint, whereas se-
verity classification did not change in the
placebo group. The change in CARS total
scores from baseline to 6-month follow up for
the risperidone group was 8% compared to 3%
for the placebo group. In addition, results from
a repeated measures ANCOVA revealed a sig-
nificant difference [ = 0.78, F (1,20) = 5.50, p <
0.05] between the risperidone and placebo
groups on the CARS Emotional Response sub-
scale when VABS Motor Skills was included as
a covariate (see Table 4).
Additional related outcome measures of in-
terest (e.g., CARS Adaptation, CARS Fear and
Nervousness, GARS Total, and VABS Social-
ization scores), expected to differ significantly
between the groups, revealed no significant
time-by-treatment interaction, even when
baseline language and motor development
were included in the equations as covariates.
Effectiveness of risperidone versus placebo on
anxiety: Baseline to 6-month follow up
A trend toward differences in change of anx-
iety symptoms was found between the risperi-
done and placebo groups using the CBCL.
This trend emerged despite a smaller sample
size due to missing data at follow up. Al-
though no differences were found between the
groups in the CBCL Internalizing T composite
scores, results from an ANOVA indicated that
differences between the two study groups’
mean scores on the CBCL Anxious/Depressed
subscale approached significance [F (1,13) =
4.42, p = 0.056]. Covariates were not included
in these analyses because there were no differ-
ences between the study groups in these areas
(e.g., motor skills, CARS scores, etc.) when
only the means for the reduced number of sub-
jects included in the analyses were calculated
(the sample sizes were reduced due to missing
data as described above).
DISCUSSION
The current study aimed to determine
whether risperidone was well tolerated and
safe in preschool aged children with ASDs. It
also aimed to investigate the short-term and 6-
month efficacy of low-dose risperidone in the
early treatment of ASDs during the preschool
period of development. The findings demon-
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strated that risperidone appeared safe and well
tolerated in this young sample over a 6-month
treatment period, with the most common en-
during side effects including weight gain, hy-
persalivation, and elevations in prolactin levels
(with no clinical lactation in any study subject).
Low levels of sedation were observed; how-
ever, all observed sedation was transient and
spontaneously resolved after several days. It
was notable that no serious adverse side effects
deemed attributable to the medication were
observed during the 6-month trial. There were
no occurrences of extraprymadial movements,
and no subjects dropped out due to side effects
of risperidone. There was a trend toward
greater elevations in leptin levels among sub-
jects on risperidone. All of these side effects are
well known from investigations of risperidone
in older children and adults. These data sug-
gest that low-dose risperidone can be given
over a 6-month period and is well tolerated by
preschool children.
The finding that differences between the
study groups were detected in the baseline to 6
month comparison and not in the four time
point repeated measures comparison is based
on the fact that the former tests are specific to a
single change, namely 6-month improvement.
By comparison, the repeated measures tests in-
volving all four time points are sensitive to
many possible differences across time and
therefore are less powerful at detecting any
specific change.
The etiology of the weight gain as well as
potential remedies, which could be used to
minimize this, should be the focus of future
study. The use of an unblinded clinician may
have diminished the occurrence of adverse
events; however, the fact that medication
dosage was lowered for only 1 subject at only
one study visit minimizes this possibility.
Study findings suggest that preschool chil-
dren treated with low-dose risperidone dis-
played greater improvements in global
measures of autism symptoms compared to
those treated with placebo. These findings
emerged only when baseline differences in de-
velopment between the two study groups
were accounted for. Specifically, differences
between study groups in CARS autism symp-
tom scores of a large effect size became evident
when baseline differences in motor skills were
controlled. Although these findings were sta-
tistically significant, the possibility of a Type I
(or Type II) error cannot be ruled out due
to the small sample size and the severity
differences between groups at baseline that
complicated the analyses. Therefore, although
findings overall are promising and suggestive
of treatment effects, we do not believe they
should be used for direct clinical practice. In-
stead, these study findings suggest that fur-
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TABLE 4. EFFICACY OF PRIMARY AND SECONDARY OUTCOMES FROM BASELINE TO 6-MONTH FOLLOW UP
Time  treatment
Baseline Endpoint interaction
Outcome Mean SD Mean SD F p
CARS totala
Risperidone (n = 11) 37.6 4.0 33.0 4.0 2.73 0.114
Placebo (n = 12) 33.3 4.9 31.5 5.1
With VABS Motor 6.92 0.16*
With PLS-3 Language 2.82 0.109
CARS Emotional Response
Risperidone (n = 11) 3.0 0.6 2.4 0.8 2.16 0.157
Placebo (n = 12) 2.3 0.8 2.2 0.5
With VABS Motor 5.50 0.029*
With PLS-3 Language 1.24 0.278
CARS = Childhood Autism Rating Scale; VABS = Vineland Adaptive Behavior Scales; PLS = Preschool Language
Scale.
aCARS Total Score: 15–29.99 “Non Autistic”; 30–36.99 “Mildly-Moderately Autistic”; 37.0–60 “Severely Autistic.”
*p < 0.05.
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ther study with larger samples and longer
treatment durations is warranted.
The original study hypothesis was that
risperidone, when used at very early points in
development, would allow for greater im-
provements in the core symptoms of autism,
including communicative language, restricted
interests, stereotypies, as well as social compe-
tence and reciprocity. Although global autism
scores appeared to improve, this study did not
detect evidence of more specific improvement
in autism core symptoms as a function of treat-
ment group. This finding is consistent with
results from double-blind treatment trials of
risperidone in older children with ASDs,
which demonstrated that despite improve-
ments in nonspecific disruptive behavior and
autism-related stereotypic behavior, the core
social and language impairments were not af-
fected by medication treatment (McCracken et
al. 2002). More recently available data from
the multisite trial (Research Units on Pediatric
Psychopharmacology Autism Network, RUPP)
of older autistic children has also shown that
whereas improvements in restricted, repeti-
tive, and stereotypic behaviors were detected,
no significant improvement in social skills or
communication emerged (McDougle et al.
2005). 
In contrast to the current findings, Shea and
colleagues (2004) found children treated with
risperidone for 8 weeks showed greater im-
provement in the core symptoms of inappro-
priate speech and lethargy/social withdrawal
in addition to decreases in stereotypic and dis-
ruptive behaviors. Given that the final mean
dose of both the Shea et al. study and the cur-
rent study were similar (0.05 mg/kg/day),
and the fact that the current study was of
longer duration, suggests that the failure of the
current study to detect differences in core
autistic features could be due to lack of statisti-
cal power related to the relatively small sam-
ple size.
Although parents and treatment providers
have held out great hope that a medication
such as risperidone might have a primary
ameliorating effect on the core symptoms of
autism, the more restricted improvements ob-
served could be expected based on the fact
that the medication was developed as an anti
psychotic to treat debilitating impairments in
emotional and behavioral control. These
symptoms, while viewed as more peripheral
to autism, are still quite disabling and, there-
fore, an important treatment target.
It was notable that both study groups im-
proved significantly over the study period, a
finding that could have been related to the on-
going developmental therapies in both groups
applied during this young age. Furthermore,
positive effects of both medication and
placebo were evident in both groups early in
the study; however, notably, the risperidone
treated group sustained gains over the 6-
month period. The important clinical implica-
tion here is that, if monitored adequately, the
beneficial effects of risperidone over placebo
should be evident after 6 months of treatment.
Although this study was only continued for 6
months, the effects gained were maintained
throughout that time. Pertinent to and extend-
ing this finding, a blinded discontinuation arm
of the RUPP Autism Network demonstrated
that risperidone showed sustained efficacy
and tolerability over a 6-month treatment pe-
riod and that discontinuation resulted in a re-
versal of these gains (RUPP Autism Network
2005). Further studies are needed to address
whether or not there are ongoing improve-
ments in behavior symptoms over longer du-
rations in autism samples treated during the
preschool period.
When baseline differences between groups
were controlled, some significant differences
in symptom improvement were evident be-
tween groups. Although the findings are not
robust, they must be viewed in light of the fact
that many study subjects also were undergo-
ing an intensive behavioral intervention. This
would suggest that differences between
groups could have been more pronounced in a
similar study group that was not also under-
going this intensive treatment. Whereas these
findings may reflect some level of improve-
ment among all children receiving risperi-
done, another possibility is that only a small
number of children treated with risperidone
demonstrated improvement in symptoms be-
yond those resulting from intensive interven-
tion. Thus, one interpretation of the findings
might be that risperidone would be most judi-
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ciously used in those children who fail to
make significant gains despite intensive
psychosocial and educational treatment. Addi-
tional double-blind, placebo-controlled treat-
ment trials in larger samples of preschool
children with ASDs, including careful safety
monitoring, are necessary before clinical use in
this age group can be recommended with con-
fidence.
Limitations
The clinical significance of the changes ob-
served are difficult to determine on the basis of
the lack of any objective measures of function-
ing beyond symptom manifestations. There-
fore, further study is still needed to determine
if the benefits outweigh the risks of this med-
ication in preschool aged children with ASDs.
These investigations should make direct com-
parisons of preschoolers in ABA treatment
with and without medication augmentation. It
is also unclear whether the dosing schedules
used by the unblinded clinician were compa-
rable to those implemented in similar studies
of this medication in older children or were
too low to produce more detectable changes. 
The findings of greater severity of ASD
symptoms and greater developmental impair-
ments in the risperidone treatment group were
limitations of the study. This, as well as the
relatively small sample size, increases the pos-
sibility of Type I and/or Type II errors. Fur-
thermore, the absence of corrections for
multiple tests for outcome analyses are an-
other clear limitation of the findings. The lack
of a more comprehensive observational as-
sessment and structured clinical interview of
autism, such as the Autism Diagnostic Obser-
vation Schedule (ADOS) and Autism Diag-
nostic Interview-Revised (ADI-R), was also a
study limitation. In addition, although safety
of the medication over the 6-month period was
established on the basis of measures of growth
and development and physiology used, the
longer-term effects of the medication on the
developing brain remain unknown and should
be the focus of future studies. Furthermore,
other metabolic measures such as insulin resis-
tance, now known to be important in atypical
antipsychotic medications, were not measured
in this investigation and should be included in
future clinical trials of risperidone in children. 
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